Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The US FDA conducted a Good Manufacturing Practices (GMP) inspection at Piramal Pharma's Sellersville, USA facility from May 4-8, 2026. At the conclusion of the inspection, the FDA issued a Form-483 with three observations. The inspectors classified the observations under VAI (Voluntary Action Indicated), which is the least serious classification and indicates the FDA is not recommending enforcement action at this time. Importantly, none of the observations relate to data integrity. The company is preparing a detailed response to address all observations and will submit it to the FDA within the stipulated timelines.
The VAI classification suggests this is a relatively minor compliance matter without immediate threat to operations, but shareholders should monitor the company's response to the FDA as unresolved observations could eventually impact product approvals or facility clearance.